The Latest Breaking News from Eisai

The success of an experimental drug offers new hope to people affected by the cruel disease.

Lecanemab found to slow decline in participants’ memory and thinking caused by the brain-wasting disease by 27 per cent

Apple is curbing iPhone production. The 10-year yield hit 4%, until the Bank of England stepped in. A Biogen Alzheimer's drug shows promise.

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease, making it the first medicine to clearly blunt progression of the most common type of dementia in a definitive, large-scale trial.

Biogen stock popped Tuesday after the company's partner, Eisai, finished submitting its application for an experimental Alzheimer's drug.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Eisai Co Ltd (OTC:ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc (NASDAQ:BIIB) for drug development. Eisai has requested a Priority Review, while the lecanemab Phase 3…

Biogen stock looks "too good to ignore," an analyst said Monday as he argued for the value of Biogen's base business.

The U.S. Medicare program’s decision to tightly limit coverage for the first drug meant to slow the course of Alzheimer’s disease has raised the stakes for companies trying to make the next one.